Alexion Announces Appointment of First Chief Diversity Officer
August 06 2020 - 8:00AM
Business Wire
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the
appointment of Uzair Qadeer as the company’s first Chief Diversity
Officer. In this new role, Mr. Qadeer will be responsible for
shaping the company’s diversity, inclusion and belonging (DI&B)
strategy, building relationships with key leaders, communities, and
organizations to create awareness and advocacy for diversity and
inclusion efforts, and advancing a unique culture of belonging for
Alexion’s patients and employees. The appointment of Mr. Qadeer
will also accelerate Alexion’s efforts to embed DI&B across the
company, spanning employee programs, corporate social
responsibility initiatives, culture efforts, and patient programs.
Mr. Qadeer will serve on Alexion’s Executive Committee, reporting
to Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200806005090/en/
Uzair Qadeer (Photo: Business Wire)
“Establishing the Chief Diversity Officer role at Alexion is an
important next step in our continued efforts to cultivate
diversity, inclusion and a unique sense of belonging at the
company, all of which enhances our ability to deliver on our
mission of transforming the lives of patients with rare diseases
and devastating conditions,” said Dr. Hantson. “Uzair has been
instrumental in helping to shape Alexion’s approach to diversity
and inclusion to date, and I am confident that, in this new role,
he will help us build a stronger, even more inclusive organization,
while ensuring every voice within the company is heard.”
Prior to assuming the role of Chief Diversity Officer, Mr.
Qadeer served as Vice President, Head of Enterprise Partnership at
Alexion, helping the company build leading-edge vision and
capabilities in executive coaching, HR business partnership, and
strategic workforce planning, while shaping the company’s initial
DI&B strategy. Before joining Alexion in February 2019, Mr.
Qadeer worked in roles of increasing responsibility in Deloitte’s
Human Capital consulting practice where he advised clients across
industries and geographies on forward-looking human capital topics
spanning talent management, organizational design and development,
human resources management, and diversity, equity and inclusion.
Prior to that, Mr. Qadeer worked at Bristol Myers Squibb Company,
expatriating to Rome, Italy and gaining deep insights in global and
international work. Additionally, Mr. Qadeer also taught at
Rutgers, The State University of New Jersey. Mr. Qadeer received
his master’s degree as well as his B.A. and B.S. degrees from
Pennsylvania State University.
“At Alexion, we believe that diversity is having a seat at the
table, inclusion is having a voice, and belonging is having that
voice be heard. Our work isn’t done until our employees and
patients can feel a true sense of belonging,” said Mr. Qadeer.
“Magnetizing and incubating diverse talent will allow us to harness
diverse insights that fuel innovation and create value for the
patients we serve. I am committed to activating this purposeful
vision.”
About Alexion Alexion is a global biopharmaceutical
company focused on serving patients and families affected by rare
diseases and devastating conditions through the discovery,
development and commercialization of life-changing medicines. As a
leader in rare diseases for more than 25 years, Alexion has
developed and commercializes two approved complement inhibitors to
treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS), as well as the first and
only approved complement inhibitor to treat anti-acetylcholine
receptor (AchR) antibody-positive generalized myasthenia gravis
(gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion
also has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D)
as well as the first and only approved Factor Xa inhibitor reversal
agent. In addition, the company is developing several
mid-to-late-stage therapies, including a copper-binding agent for
Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for
rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D
inhibitor as well as several early-stage therapies, including one
for light chain (AL) amyloidosis, a second oral Factor D inhibitor
and a third complement inhibitor. Alexion focuses its research
efforts on novel molecules and targets in the complement cascade
and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, metabolic disorders and
cardiology. Headquartered in Boston, Massachusetts, Alexion has
offices around the globe and serves patients in more than 50
countries. This press release and further information about Alexion
can be found at: www.alexion.com.
[ALXN-G]
Forward-Looking Statement This press release contains
forward-looking statements, including statements related to: the
Company’s planned implementation of the diversity, inclusion and
belonging (DI&B) strategy; the expected benefits of the
DI&B strategy and its implementation; the acceleration of
Alexion’s efforts to embed DI&B across the organizational
ecosystem, spanning employee programs, corporate social
responsibility initiatives, culture efforts, and patient programs;
the Company will continue efforts to cultivate diversity, inclusion
and a unique sense of belonging at the Company, all of which
enhances our ability to deliver on our mission of transforming the
lives of patients with rare diseases and devastating conditions;
and the Chief Diversity Officer will help build a stronger, even
more inclusive organization. Forward-looking statements are subject
to factors that may cause Alexion's results and plans to differ
materially from those forward-looking statements, including for
example: the Company may not be able to implement its planned
DI&B initiatives, the Company may not realize the benefits from
the DI&B initiatives contemplated by the Company; the Company
may not be able to implement some or all of its DI&B plans; our
dependence on sales from our principal product (SOLIRIS); our
ability to facilitate the timely conversion from SOLIRIS to
ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as
an alternative to SOLIRIS; the impact of the COVID-19 pandemic on
Alexion’s business, including its sales, clinical trials,
operations, DI&B and HR initiatives, and supply chain; future
competition from biosimilars and novel products; decisions of
regulatory authorities regarding the adequacy of our research,
marketing approval or material limitations on the marketing of our
products; delays or failure of product candidates to obtain
regulatory approval; delays or the inability to launch product
candidates due to regulatory restrictions, anticipated expense or
other reasons; results in early stage clinical trials may not be
indicative of full results or results from later stage or larger
clinical trials (or in broader patient populations) and do not
ensure regulatory approval; the possibility that current rates of
adoption of our products are not sustained; the adequacy of our
pharmacovigilance and drug safety reporting processes; failure to
protect and enforce our data, intellectual property and proprietary
rights and the risks and uncertainties relating to intellectual
property claims, lawsuits and challenges against us (including
intellectual property lawsuits relating to ULTOMIRIS brought by
third parties against Alexion); the risk that third party payors
(including governmental agencies) will not reimburse or continue to
reimburse for the use of our products at acceptable rates or at
all; potential declines in sovereign credit ratings or sovereign
defaults in countries where we sell our products; delay of
collection or reduction in reimbursement due to adverse economic
conditions or changes in government and private insurer regulations
and approaches to reimbursement; uncertainties surrounding legal
proceedings, company investigations and government investigations;
the risk that estimates regarding the number of patients with PNH,
aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are
pursuing are inaccurate; and a variety of other risks set forth
from time to time in Alexion's filings with the SEC, including but
not limited to the risks discussed in Alexion's Quarterly Report on
Form 10-Q for the period ended June 30, 2020 and in our other
filings with the SEC. Alexion disclaims any obligation to update
any of these forward-looking statements to reflect events or
circumstances after the date hereof, except when a duty arises
under law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806005090/en/
Alexion: Media Katie Payne, 202-669-6786 VP,
External Communications
Investors Chris Stevo, 857-338-9309 Head of Investor
Relations
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024